By vgreene, 17 June, 2019 EGFR mutation testing in never smokers or small bx specimens, or mixed histology
By vgreene, 17 June, 2019 Broad molecular profiling1 to identify rare drive mutations for which effective drugs may already be available, or to better counsel pts re clinical trial availability
By vgreene, 17 June, 2019 ALK testing (category 1):1,2 IHC is an equivalent alternative to FISH for ALK testing2
By vgreene, 17 June, 2019 EGFR mutation testing (category 1) NCCN recommends EFGR (exon 19 deletions, p.L858R point mutation in exon 21 assoc w/ responsiveness to EGFR TKI tx); 1 but ASCO strongly recommends against evaluating EFGR by immunohistochemistry for selection of pts for